Aptevo Therapeutics (APVO) Assets Average (2016 - 2026)
Aptevo Therapeutics (APVO) posted Assets Average of $23.5 million for Q1 2026, down 13.09% sequentially from $27.1 million in Q4 2025, and up 96.78% YoY from $12.0 million in Q1 2025.
Aptevo Therapeutics (APVO) Assets Average (2016 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Assets Average for 11 years, with the latest figure at $23.5 million in Q1 2026.
- Quarterly Assets Average rose 96.78% year-over-year to $23.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.5 million (up 96.78% YoY) and the FY2025 annual result came in at $21.4 million, up 5.82% from the prior year.
- Assets Average retreated to $23.5 million in Q1 2026 per APVO's latest filing, from $27.1 million in the prior quarter.
- Over five years, Assets Average peaked at $50.9 million in Q1 2022 and troughed at $12.0 million in Q1 2025.
- A 5-year average of $26.2 million and a median of $26.0 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2026: Assets Average slumped 49.05% in 2024, then soared 96.78% in 2026.
- Over 5 years, Assets Average stood at $33.0 million in 2022, then fell by 21.15% to $26.0 million in 2023, then slumped by 40.86% to $15.4 million in 2024, then jumped by 76.3% to $27.1 million in 2025, then dropped by 13.09% to $23.5 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $23.5 million, $27.1 million, and $21.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | 17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.21 Mn |
| Mar 31, 2026 | 23.55 Mn |
| Dec 31, 2025 | 27.10 Mn |
| Sep 30, 2025 | 21.31 Mn |
| Jun 30, 2025 | 11.98 Mn |
| Mar 31, 2025 | 11.97 Mn |
| Dec 31, 2024 | 15.37 Mn |
| Sep 30, 2024 | 15.03 Mn |
| Jun 30, 2024 | 16.28 Mn |
| Mar 31, 2024 | 21.24 Mn |
| Dec 31, 2023 | 25.99 Mn |
| Sep 30, 2023 | 28.02 Mn |
| Jun 30, 2023 | 31.94 Mn |
| Mar 31, 2023 | 34.59 Mn |
| Dec 31, 2022 | 32.96 Mn |
| Sep 30, 2022 | 35.25 Mn |
| Jun 30, 2022 | 41.99 Mn |
| Mar 31, 2022 | 50.89 Mn |
| Dec 31, 2021 | 60.30 Mn |
| Sep 30, 2021 | 67.74 Mn |